The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

$80,000 of MERCK KGAA DARMSTADT GERMANY lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to chemical ...

Dr. Michael Har-Noy, Founder and Chief Medical Officer of Mirror Biologics stated: “We are pleased to enter into this ...

This follows a successful two-year validation study with Merck KGaA, Darmstadt, Germany, in which Quris-AI delivered a significantly higher accuracy in detecting drug-induced liver injury (DILI ...

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna. The agreement gives ...

Nvidia CEO Jensen Huang may have said that "very useful quantum computers" are probably still 20 years away, but his company ...

Merck KGaA is shaping up to take on Daiichi ... therapies after its drug candidate pimicotinib cleared a phase 3 trial. The German group said the CSF-1R inhibitor given as a once-daily, oral ...

Merck has just released a cyber-to-physical platform that uses crypto anchor technology and other tools to help crush the counterfeit product market.